OPINION:
Colorectal cancer, the second-leading cause of cancer death in the United States, is highly preventable and treatable when detected early.
Most colon cancers start as slow-growing polyps. With proven screening methods, polyps can be identified and removed, preventing a cancer diagnosis.
My own colonoscopy found precancerous polyps. They were removed, and I am convinced that screening saved my life. As both a physician and a patient who caught the disease in time, I know screening is critical.
People were interested in these podcasts
Unfortunately, too few people are getting screened. Adults ages 45 to 49 are eligible for screening and account for half of all diagnoses before age 50, yet only 37% are up to date on testing.
It is also important that screening methods be the most effective at identifying these polyps. New tools are entering the market, and although some appear promising, there are serious issues to consider.
The primary concerns come from blood tests. The shortcomings of these tests are evident. Precancerous polyps have not invaded surrounding tissue, so they shed little detectable DNA into the blood.
In the pivotal study behind the first blood test approved by the Food and Drug Administration as a primary screening option for colorectal cancer, the test caught only about 13% of advanced precancerous lesions, or roughly 1 in 8. It also missed about one-third of Stage I cancers, the stage at which this disease is most curable.
A test that mostly finds cancer after it has formed is an early detection tool, but it is not prevention, and we should not let patients believe it is. A person who picks a blood test over a stool-based test or colonoscopy because it seems easier may be giving up the chance to stop cancer before it starts, often without being aware of the trade-off.
That is why I previously urged the Centers for Medicare & Medicaid Services to ensure that its coverage framework supports tests that demonstrate meaningful sensitivity for advanced precancerous lesions, not just cancer. Coverage decisions shape what doctors offer and what patients choose. The standard should match the goal.
Patients deserve screening tests that meet the highest standards of care. That is especially important for colorectal cancer, one of the most preventable forms of cancer, where the right test can do more than detect disease — it can prevent cancer.
The National Committee for Quality Assurance maintains quality measures used in Medicare’s star ratings that recognize colonoscopy, stool-based tests and other established screening methods. Blood tests are not currently included. That distinction matters, and it should remain in place until blood tests can reliably detect precancerous lesions and demonstrate their ability to prevent cancer, not simply detect it after it develops.
It is essential that we promote innovation in cancer screening and prevention measures. I would never discourage research that could save lives, and I hope the next generation of blood tests closes this gap. Yet they must prove they can meet the high standards already established in at-home care.
Stool-based tests that can detect precancers are proven and highly effective options — and we owe patients a high bar for anything we steer them toward instead, as we pursue a true preventive care model.
Public health experts often say that the best screening test is the one that gets done. That is true. Yet it should also be one that can get the job done.
• Dr. Jerome Adams served as the 20th surgeon general of the United States from 2017 to 2021.

Please read our comment policy before commenting.